Vivos Therapeutics (VVOS) EBIT Margin (2020 - 2025)
Historic EBIT Margin for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to 69.79%.
- Vivos Therapeutics' EBIT Margin fell 12700.0% to 69.79% in Q3 2025 from the same period last year, while for Sep 2025 it was 94.26%, marking a year-over-year decrease of 85400.0%. This contributed to the annual value of 74.32% for FY2024, which is 510000.0% up from last year.
- Vivos Therapeutics' EBIT Margin amounted to 69.79% in Q3 2025, which was down 12700.0% from 127.36% recorded in Q2 2025.
- In the past 5 years, Vivos Therapeutics' EBIT Margin registered a high of 47.76% during Q2 2024, and its lowest value of 182.19% during Q1 2022.
- Moreover, its 5-year median value for EBIT Margin was 127.25% (2023), whereas its average is 117.82%.
- In the last 5 years, Vivos Therapeutics' EBIT Margin crashed by -834100bps in 2022 and then soared by 852900bps in 2024.
- Quarter analysis of 5 years shows Vivos Therapeutics' EBIT Margin stood at 168.66% in 2021, then increased by 9bps to 153.49% in 2022, then grew by 17bps to 127.25% in 2023, then surged by 40bps to 75.88% in 2024, then grew by 8bps to 69.79% in 2025.
- Its last three reported values are 69.79% in Q3 2025, 127.36% for Q2 2025, and 129.91% during Q1 2025.